Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification

Journal of Addictive Diseases

Volumn 25, Issue 4, 2006, Pages 27-35

  Davison, John W ^f   Sweeney, Marie L ^a   Bush, Kristen R ^a,b   Correale, Tania M Davis ^a,b,c   Calsyn, Donald A ^a,b,c,d   Reoux, Joseph P ^a,c   Sloan, Kevin L ^a,c   Kivlahan, Daniel R ^a,b,c,d,e  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b Center of Excellence in Substance Abuse Treatment and Education   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Education and Clinical Center   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Antagonist; Chronic opioid dependence; Naltrexone; Opioid detoxification; Outpatient treatment

Indexed keywords

CLONIDINE; NALTREXONE; OPIATE;

ABSTINENCE; ADULT; AFTERCARE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DETOXIFICATION; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH SERVICE; OPIATE ADDICTION; OUTPATIENT CARE; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY;

AFTERCARE; AMBULATORY CARE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PSYCHOTHERAPY, GROUP; TIME FACTORS; TREATMENT OUTCOME; VETERANS;

EID: 33750712359     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n04_03     Document Type: Article

References (33)

1. National Institute of Health. Effective Medical Treatment of Opiate Addiction. NIH Consensus Statement 1997 Nov 17-19;15(6):1-38.
2. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Year-End 2000 Emergency Department Data from the Drug Abuse Warning Network. DAWN Series D-18, DHHS Publication No. (SMA) 01-3532. Rockville, MD; 2001.
3. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Drug Abuse Warning Network, 2003: Area Profiles of Drug-Related Mortality. DAWN Series D-27, DHHS Publication No. (SMA) 05-4023. Rockville, MD; 2005.
4. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights-2003: National Admissions to Substance Abuse Treatment Services. DASIS Series: S-27, DHHS Publication No. (SMA) 05-4043. Rockville, MD; 2005.
5. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 42. DHHS Publication No. (SMA) 05-3922. Rockville, MD: Substance Abuse Mental Health Services Administration; 2005.
6. Etheridge RM, Hubbard RL, Anderson J, Craddock SG, Flynn PM. Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997;11:244-260.
7. Magura S, Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001;68:62-74.
8. DeLeon G. Recent research into therapeutic communities. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries R, Wilford B, editors. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003, pp. 929-930.
9. Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997;11:261-268.
10. Vidjak N. Treating heroin addiction: Comparison of methadone therapy, hospital therapy without methadone, and therapeutic community. Croat Med J 2003;44:59-64.
11. Lewis BF, Ross R. Retention in therapeutic communities: challenges for the nineties. In: Tims FM, DeLeon G, Jainchill N, editors. Therapeutic community: advances in research and application, NIDA Research Monograph 144. Rockville, MD: National Institute on Drug Abuse; 1994, pp. 99-116.
12. Greenwood GL, Woods WJ, Guydish J, Bein E. Relapse outcomes in a randomized trial of residential and day drug abuse treatment. J Subst Abuse Treatment 2001;20:15-23.
13. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA 2000;283:1303.
14. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA 1995;273:1619.
15. National Institute on Drug Abuse. Methadone in maintenance and detoxification: Joint revision of conditions on use. Federal Register 1989;54:8954.
16. Rettig RA, Yarmonlinsky A, editors. Federal regulation of methadone treatment. Washington DC: National Academic Press; 1995.
17. McCarty D, Frank RG, Denmead GC. Methadone maintenance and state medicaid managed care programs. Milbank Q 1999;77:341-362.
18. Trafton J, Barnett P, Finney J, et al. Effective treatment for opioid dependence. VA Practice Matters 2001;6(2):1-6.
19. Kosten RT, O'Connor PG. Management of drug and alcohol withdrawl. New Engl J Med 2003;348: 1786-1795.
20. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alc Abuse 2001;27:19-44.
21. Volpicelli JR, Alterman AL, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol depedence. Arch Gen Psychiatr 1992;49:876-880.
22. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence: The Cochrane Database of Systematic Reviews; 2003.
23. Comer SD, Sullivan MA, Yu E, Rothenber JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry, 2006;63(2):210-8.
24. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alc Depend 2000;58:85-92.
25. McCusker J, Bigelow C, Luippold R, Zorn M, Lewis BF. Outcomes of a 21-day drug detoxification program: Retention, transfer to further treatment, and HIV risk reduction. Am J Drug Alcohol Abuse 1995; 21(1):1-16.
26. Marlatt GA, Gordon J. Relapse Prevention. New York: Guilford Press; 1985.
27. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. Br J of Psychiatry 1989;154:348-353.
28. Simpson DD, Joe GW, Bracy SA. Six-year follow-up of opioid addicts after admission to treatment. Arch of Gen Psych 1982;39:1318.
29. Barnett P. The cost-effectiveness of methadone maintenance treatment. Addiction 1999;91:479.
30. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998;52:257.
31. Caplehorn JRM, Dalton MS, Haldar F, Petrenas A, Nisbet JG. Methadone maintenance addicts' risk of fatal heroin overdose. Subst Use Misuse 1996;31:177-196.
32. McLellan AT, Alterman AI, Metzger DS, Grissom GR, Woody GE, Luborsky L, et al. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: Role of treatment services. J Consult Clin Psychol 1994;62:1141-1158.
33. McLellan AT, Metzger DS, Alterman AI, Cornish J, Uschrel H. How effective is substance abuse treatment-compared to what? In: O'Brien CP JJ, editor. Advances in understanding the addictive states. New York: Association for Research in Nervous and Mental Disorders Press.; 1992, pp. 312-337.